Brief: HOOKIPA Pharma EMA Grants Prime Designation For Investigational Product HB-200 In Combination With Pembrolizumab
10/04/2024 12:17
April 10 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* HOOKIPA PHARMA INC: EMA HAS GRANTED PRIME DESIGNATION FOR
INVESTIGATIONAL PRODUCT HB-200 IN COMBINATION WITH PEMBROLIZUMAB
Source text for Eikon: ID:nGNX2YQf68
Further company coverage: HOOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)